The candidate has been approved under the brand name Attruby. BBIO stock surged on the news. The FDA approval is based on positive results from the phase III ATTRibute-CM study, in which Attruby ...
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...
Stocktwits on MSN8d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement BuildsBridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
On Monday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $22.35 which represents a decrease of $-1.37 or -5.78% from the prior close of $23.72. The stock opened at $23.32 and ...
Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
14d
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating on November 15.Don't Miss our ...
Zacks.com on MSN4d
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MorePipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback